首页|Clinical characteristics and outcomes of psoriasis patients with COVID-19:A retrospective,multicenter cohort study in China

Clinical characteristics and outcomes of psoriasis patients with COVID-19:A retrospective,multicenter cohort study in China

扫码查看
原文链接
  • 国家科技期刊平台
  • NETL
  • NSTL
  • 万方数据
Background:Limited information exists regarding the impact of severe acute respiratory syndrome-coronavirus-2(SARS-CoV-2)infection on psoriasis patients.The objective of this study was to identify clinical factors associated with the prognosis of psoriasis following SARS-CoV-2 infection.Methods:A retrospective,multicenter study was conducted between March and May 2023.Univariable and multivariable logistic regression analyses were employed to identify factors associated with coronavirus disease 2019(COVID-19)-related psoriasis out-comes.The study included 2371 psoriasis patients from 12 clinical centers,with 2049 of them having been infected with SARS-CoV-2.Results:Among the infected groups,lower exacerbation rates were observed in individuals treated with biologics compared to those receiving traditional systemic or nonsystemic treatments(22.3％[236/1058]vs.39.8％[92/231]vs.37.5％[140/373],P＜0.001).Psoriasis progression with lesions(adjusted odds ratio[OR]=8.197,95％confidence interval[95％CI]=5.685-11.820,compared to no lesions),hypertension(adjusted OR=1.582,95％CI=1.068-2.343),traditional systemic(adjusted OR=1.887,95％CI=1.263-2.818),and nonsystemic treatment(adjusted OR=1.602,95％CI=1.117-2.297)were found to be associated with exacerbation of psoriasis after SARS-CoV-2 infection,but not biologics(adjusted OR=0.931,95％CI=0.680-1.274,compared to no treatment),according to multivariable logistic regression analysis.Conclusions:A reduced risk of psoriasis exacerbation after SARS-CoV-2 infection was observed with biologics compared to traditional systemic and nonsystemic treatments.Significant risk factors for exacerbation after infection were identified as existing psoriatic lesions and hypertension.

COVID-19SARS-CoV-2PsoriasisTreatmentBiologics

Yanhua Liu、Zhongrui Xu、Jian Zhou、Aijun Chen、Junling Zhang、Xiaojing Kang、Xian Jiang、Chengzhi Lyu、Chunrui Shi、Yuling Shi、Xiaoming Liu、Fuqiu Li、Bin Yang、Yongmei Huang、Chen Yu、Gang Wang

展开 >

Department of Dermatology,Xijing Hospital,Fourth Military Medical University,Xi'an,Shaanxi 710032,China

Department of Dermatology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China

Department of Dermatology,Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital,Tianjin 300072,China

Department of Dermatology and Venereology,People's Hospital of Xinjiang Uygur Autonomous Region,Urumqi,Xinjiang 830001,China

Department of Dermatology,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China

Department of Psoriasis,Dalian Dermatosis Hospital,Dalian,Liaoning 116011,China

Department of Dermatology,The First Hospital of Lanzhou University,Lanzhou,Gansu 730000,China

Skin Disease Hospital of Tongji University,Shanghai 200050,China

Department of Dermatology,The University of Hong Kong-Shenzhen Hospital,Shenzhen,Guangdong 518053,China

Department of Dermatology,The Second Hospital of Jilin University,Changchun,Jilin 130000,China

Department of Dermatology,Dermatology Hospital of Southern Medical University,Guangzhou,Guangdong 510091,China

Department of Dermatology,Xining First People's Hospital,Xining,Qinghai 810000,China

展开 >

Clinical Research Project on COVID-19 infection at the Xijing Hospital

XJZT23XG29

2024

10.1097/CM9.0000000000003024

中华医学杂志(英文版)
中华医学会

中华医学杂志(英文版)

CSTPCD
影响因子：0.838
ISSN：0366-6999
年,卷(期)：2024.137(14)
  • 32